ArticleObstetrics & gynecology science2026
Hybrid surgical approach for advanced ovarian cancer: hybrid approach for robotic and minimal open abdominal cytoreduction technique.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
objectiveTo assess the feasibility of a hybrid surgical approach combining robotic-assisted pelvic and laparotomic upper abdominal cytoreduction for advanced ovarian cancer.
methodsWe retrospectively reviewed 20 patients with International Federation of Gynecology and Obstetrics stage III-IV ovarian cancer at the National Cancer Center, Korea, who underwent this hybrid approach between July 2023 and September 2024. Robotic surgery was performed for pelvic procedures, whereas upper abdominal cytoreduction was performed through a small laparotomy. Surgical outcomes included residual tumor status, operation time, estimated blood loss, complications, and postoperative recovery.
resultsThe median age was 53 years, with 75% of patients diagnosed with high-grade serous carcinoma. The median operation time was 342.5 minutes (range, 200.0-505.0) and the median blood loss was 300 mL (range, 5.0-1,500.0). No gross residual disease was achieved in 95% of patients. Intraoperative complications occurred in two patients (10.0%). The median hospital stay was 8 days (range, 6.0-14.0). Foley catheter removal and the first bowel gas passage occurred at a median of 3.5 and 3.0 postoperative days, respectively. Postoperative complications within 30 days included ileus (10.0%), pleural effusion (10.0%), bowel perforation (5.0%), thromboembolism (5.0%), and wound complications (5.0%). Adjuvant chemotherapy began at a median of 17 days postoperatively (range, 10.0-36.0) and 15% of patients were readmitted for ileus, wound complications, or bowel perforation.
conclusionThis hybrid approach demonstrates feasibility with acceptable morbidity in a selected cohort; however, the absence of a comparator group precludes conclusions regarding superiority over conventional approaches. Further prospective studies are required to validate these findings and evaluate long-term oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.